gastric cancer, esophageal cancer, soft tissue sarcoma
Conditions
Interventions
None listed
Sponsors
Institute of Development, Aging and Cancer Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) confirmed gastric cancer, esophageal cancer or soft tissue sarcoma by histopathological diagnosis 2) inoperable and recurrent gastric cancer, esophageal cancer or soft tissue sarcoma, and those who are planned or performed chemotherapy 3) age: >=20 4) Performance status(ECOG) =0-2 5) Only the case who will survive three months or more from enrollment 6) written informed consent
Exclusion criteria
Exclusion criteria: 1) with active infection (more than 38 degree) 2) with the following heart disorder or state ->A history of previous congestive heart failure ->High-risk cardiac arrhythmia that is impossible to control ->Clinical serious heart valve disease ->Hypertension (e.g. patients with systolic blood pressure> 180mmHg or diastolic blood pressure> 100mmHg) 3) with serious complications (interstitial pneumonia, pulmonary fibrosis, heart failure, renal failure, hepatic failure or diabetes mellitus inadequate control) 4) with active bleeding from gastric cancer, esophageal cancer or gastrointestinal ulcer 5) with multiple primary cancer keeping activity 6) receiving systemic steroid therapy continuously 7) A pregnant woman or woman with pregnant possibility 8) Doctor's decision not to be registered to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We examine the utility of S1P as novel tumor marker. | — |
Secondary
| Measure | Time frame |
|---|---|
| We examine correlation between S1P value and response rate(RR), progression-free survival(PFS) and overall survival(OS). | — |
Countries
Japan
Contacts
Public ContactShin Takahashi
Institute of Development, Aging and Cancer Tohoku University Department of Clinical Oncology
Outcome results
None listed